A phase Ib/II study to assess the safety and preliminary efficacy of PM8002 in combination with nab-paclitaxel in patients with triple-negative breast cancer

被引：0
|
作者：
Wu, Jiong
Zhang, Jian
Tong, Zhongsheng
Wang, Yongsheng
Zhang, Qingyuan
Cheng, Qiao
Chen, Xin
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[3] Shandong Canc Hosp & Inst, Jinan, Peoples R China
[4] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[5] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China
[6] Second Peoples Hosp Yibin, Yibin, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13091
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety
    Vishnu, K. Sharmni
    Win, Thin Thin
    Aye, Saint Nway
    Basavaraj, Arun Kumar
    BMC CANCER, 2022, 22 (01)
  • [32] Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
    Zefei Jiang
    Quchang Ouyang
    Tao Sun
    Qingyuan Zhang
    Yuee Teng
    Jiuwei Cui
    Haibo Wang
    Yongmei Yin
    Xiaojia Wang
    Xin Zhou
    Yongsheng Wang
    Gang Sun
    Jingfen Wang
    Lili Zhang
    Jin Yang
    Jun Qian
    Min Yan
    Xinlan Liu
    Tienan Yi
    Ying Cheng
    Man Li
    Aimin Zang
    Shusen Wang
    Chuan Wang
    Xinhong Wu
    Jing Cheng
    Hui Li
    Ying Lin
    Cuizhi Geng
    Kangsheng Gu
    Chunwei Xie
    Huihua Xiong
    Xiaohong Wu
    Junlan Yang
    Qingshan Li
    Yiding Chen
    Fanfan Li
    Anqin Zhang
    Yongqiang Zhang
    Yudong Wu
    Jianyun Nie
    Qiang Liu
    Kun Wang
    Xueli Mo
    Lilin Chen
    Yueyin Pan
    Peifen Fu
    Helong Zhang
    Danmei Pang
    Yuan Sheng
    Nature Medicine, 2024, 30 : 249 - 256
  • [33] Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety
    K. Sharmni Vishnu
    Thin Thin Win
    Saint Nway Aye
    Arun Kumar Basavaraj
    BMC Cancer, 22
  • [34] Phase II study of sitravatinib plus tislelizumab with or without nab-paclitaxel in patients with locally recurrent or metastatic triple negative breast cancer
    Fan, Lei
    Liu, Xiyu
    Xu, Ying
    Sui, Xinyi
    Zhang, Wenjuan
    Ma, Linxiaoxi
    Jin, Xi
    Wu, Song-Yang
    Wang, Han
    Xiao, Yi
    Chen, Li
    Wu, Jiong
    Yu, Ke-da
    Liu, Guangyu
    Hu, Xin
    Wang, Zhonghua
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    CANCER RESEARCH, 2024, 84 (09)
  • [35] In vitro cytotoxic effect of PARP inhibitor alone and in combination with nab-paclitaxel on triple-negative and luminal A breast cancer cells
    Topcul, Mehmet
    Cetin, Idil
    Turan, Suna Ozbas
    Ozar, Melek Ozlem Kolusayin
    ONCOLOGY REPORTS, 2018, 40 (01) : 527 - 535
  • [36] Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer
    Kwa, Maryann J.
    Iwano, Alyssa
    Esteva, Francisco J.
    Novik, Yelena
    Speyer, James L.
    Oratz, Ruth
    Meyers, Marleen Iva
    Axelrod, Deborah M.
    Hogan, Rebecca
    Mendoza, Sandra
    Goldberg, Judith D.
    Muggia, Franco
    Adams, Sylvia
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives
    Schettini, Francesco
    Giuliano, Mario
    De Placido, Sabino
    Arpino, Grazia
    CANCER TREATMENT REVIEWS, 2016, 50 : 129 - 141
  • [38] Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer
    Luhn, Patricia
    Chui, Stephen Y.
    Hsieh, Fu-Chi
    Yi, Jingbo
    Mecke, Almut
    Bajaj, Preeti S.
    Hasnain, Waseem
    Falgas, Adeline
    Ton, Thanh G. N.
    Kurian, Allison W.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (14) : 1173 - 1185
  • [39] Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
    Wang, Chengzheng
    Liu, Zhenzhen
    Chen, Xiuchun
    Qiao, Jianghua
    Lu, Zhenduo
    Li, Lianfang
    Sun, Xianfu
    Zhang, Chongjian
    Yue, Xiayu
    Xia, Qingxin
    Zhang, He
    Yan, Min
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [40] Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
    Chengzheng Wang
    Zhenzhen Liu
    Xiuchun Chen
    Jianghua Qiao
    Zhenduo Lu
    Lianfang Li
    Xianfu Sun
    Chongjian Zhang
    Xiayu Yue
    Qingxin Xia
    He Zhang
    Min Yan
    Nature Communications, 14 (1)
12345